Emami Reports Q4FY26 Results; Core Domestic Portfolio Remains Resilient Amid External Headwinds
EMAMILTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emami reported Q4FY26 consolidated revenues of ₹925 crore, down 4% YoY, impacted by a disrupted summer season and geopolitical disruptions in West Asia affecting its international business. Gross margins expanded 250 bps to 68.4% due to cost discipline and pricing actions. EBITDA fell 15% to ₹187 crore while PAT declined ~12% to ₹143 crore. For the full year FY26, revenues stood at ₹3,780 crore with EBITDA at ₹964 crore and PAT at ₹775 crore. Despite the topline decline, the non-summer domestic portfolio delivered healthy 11% growth, and organised channels now contribute ~32% of domestic business. The company made two strategic investments — increasing stake in Axiom Ayurveda (making it a subsidiary) and acquiring majority stake in IncNut (Vedix, SkinKraft) — to expand into health beverages and personalised BPC. The balance sheet remains debt-free with net cash of ₹883 crore. Dividend of ₹10 per share was declared, representing a 51% payout.
Near-term pressure from seasonal and geopolitical headwinds is evident in the revenue and EBITDA decline, but margin expansion and strategic acquisitions signal long-term growth positioning. The company's debt-free status and strong cash position provide resilience for future investments.